Forecast

There is no analyst data available for this company.

News Go to news feed

Evolv expands partnership with Gillette Stadium and becomes official provider for fan security screening

Evolv has renewed and expanded its partnership with Gillette Stadium, which began in 2021, so that KI-supported Evolv Express security lanes will be installed at additional entrances. The systems are designed to detect concealed weapons at normal walking speed and have already screened more than seven million visitors at the stadium. The contract extension strengthens Evolv’s presence in the greater Boston area; the company reports 36.6% revenue growth last year, Q2 revenue of $32.5 million (+29%) and remains unprofitable despite strong demand (negative EBITDA). Analyst reactions raised price targets and ratings but highlighted the still-present valuation premium. » More on de.investing.com
Evolv Technologies reaches new 52-week high at $7.45

Shares of Evolv Technologies Holdings Inc. rose to a new 52-week high of $7.45 after the stock gained about 143.77% over the past year. The company reported revenue growth of 36.71%, a positive EBITDA in the first quarter, a $75 million credit facility from MidCap Financial and a $19.36 million school contract with Gwinnett Schools; analyst price targets range from $5.50 to $8.25. Positive analyst revisions (Northland, Craig-Hallum, Lake Street) and the resolution of an FTC probe are cited as drivers of the optimistic sentiment. » More on de.investing.com
Evolv Technologies reaches new 52-week high after strong growth and positive analyst ratings

Evolv Technologies' stock climbed to a 52-week high of $7.10, supported by revenue growth of 36.71% and strong performance over the past year. The company also secured a $75 million credit facility to strengthen its subscription-based business and significantly exceeded revenue expectations in the first quarter. Analysts upgraded the stock to 'Outperform' or 'Buy' due to improved financial metrics and strategic initiatives. » More on de.investing.com

Financials

In the last quarter, EVOLVA N had revenue of 0.00€ and net profit of −313.08k€

(EUR)	Dec 2025	YoY
Revenue	0.00	-
Gross profit	0.00	-
Net profit	−313.08k	-
EBITDA	0.00	-

Fundamentals

Metric	Value
Market capitalization	+18.16m€
Number of shares	7.21m
52-week high/low	+21,96€ - +0,66€
Dividends	No
Beta	-0,05
P/E ratio	−26,44
PEG ratio	+0,12
P/B ratio	+2,90
P/S ratio	0,00

Company profile

Evolva Holding SA entdeckt, erforscht, entwickelt und vermarktet Inhaltsstoffe auf natürlicher Basis, die in der Schweiz, in den Vereinigten Staaten und international in den Bereichen Aromen und Düfte, gesundheitliche Inhaltsstoffe, Gesundheitsschutz und in anderen Sektoren verwendet werden. Das Unternehmen bietet verschiedene Inhaltsstoffe an, darunter Veri-te Resveratrol, ein natürliches Polyphenol, das in Weintrauben und anderen Pflanzen, einschließlich Erdnüssen, Cranberries und Beeren, vorkommt; L-Arabinose, ein Aromastoff, der bei der Maillard-Reaktion verwendet wird; Valencen, ein Aromabestandteil von Zitrusfrüchten und aus Zitrusfrüchten gewonnenen Duftstoffen; Nootkaton, ein Aromabestandteil von Grapefruit, der durch biochemische Oxidation von Valencen gewonnen wird; und Vanillin, ein Hauptbestandteil von Vanilleschotenextrakt. Das Unternehmen wurde 2004 gegründet und hat seinen Hauptsitz in Reinach, Schweiz.